UTHR — United Therapeutics Share News
0.000.00%
Last trade - 00:00- $25.46bn
- $22.80bn
- $3.18bn
Brief: United Therapeutics Enters Credit Agreement With Wells Fargo - SEC Filing
U.S. STOCKS ON THE MOVE-AerCap Holdings, Salesforce, Emcor Group
U.S. STOCKS ON THE MOVE-Cheesecake Factory, SiriusPoint, Arcutis Biosciences
United Therapeutics Corp reports results for the quarter ended December 31 - Earnings Summary
United Therapeutics Corp expected to post earnings of $6.31 a share - Earnings Preview
Brief: United Therapeutics Fully Enrolls Teton 1 Study Of Inhaled Treprostinil For Idiopathic Pulmonary Fibrosis
Brief: United Therapeutics Gets FDA Clearance for uKidney Xenotransplantation Clinical Trial
Electric planemaker Beta Technologies raises over $300 mln in new funding
United Therapeutics Corp reports results for the quarter ended in September 30 - Earnings Summary
Brief: United Therapeutics Corporation Reports Third Quarter 2024 Financial Results
Brief: United Therapeutics Q3 Revenue USD 748.9 Million Vs. IBES Estimate USD 722.6 Million
U.S. RESEARCH ROUNDUP-Cardinal Health, Factset, Paylocity Holding
Brief: Liquidia Corp United Therapeutics Filed New Cross-Claims In FDA Suit Against FDA
Liquidia down after challenging regulatory exclusivity for rival's inhaled drug
Liquidia down after co challenges regulatory exclusivity for rival's inhaled drug
Liquidia challenges regulatory exclusivity for rival's inhaled drug (updated)
Liquidia files litigation challenging regulatory exclusivity for rival's inhaled drug
Liquidia slumps as US FDA holds back final approval for blood pressure drug
US FDA grants tentative approval to Liquidia's inhaled blood pressure drug (updated)